New ARV-based prevention tools how the research is happening how we need to be involved Anna Forbes, MSS Consultant, HIV and women’s health HIV Research.

Slides:



Advertisements
Similar presentations
What does sexual & reproductive health have to do with clinical trials? Providing contraception & reproductive health care helps.
Advertisements

No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.
STDs Valerie Robinson D.O.. Prevention Abstinence Risk reduction Vaccines Male or female condoms Cervical diaphragm might protect against cervical GC,
Cristin Muecke, RMOH Nick Scott, ED AIDS NB.  Why HIV testing remains important  Treatment as prevention  Discuss advantages/disadvantages of various.
Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.
From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.
Microbicides Envision a product that could save lives Your name here
What is it? How may it help women? PrEP. What is PrEP? How would it work? What do we know about it? When will we know more? What could it mean for women?
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Hadiyah Charles, Community HIV/AIDS Mobilization Project Naina Khanna, WORLD/U.S. Positive Women’s Network HIV Research Catalyst Forum April 21, 2010.
New Prevention Technologies Workshop Module 3: Overview of Prevention Research
Rectal Microbicides: The Basics Date, Location Your name, Your affiliation.
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Use of Antivirals in Prevention Oral and Topical Prophylaxis
Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.
Rectal Microbicides: The Basics Date, Location Your Name, Organization.
Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.
EngenderHealth/UNFPA Project – Ethiopia/Ukraine Strengthening the integration of HIV prevention in maternal health services. Increasing the capacity of.
Introduction to HIV New Prevention Technologies (NPTs)
Microbicides: New Hope for Prevention of HIV and other STIs
Summarising Male Circumcision Efficacy: Results of the three randomised clinical trials Neil A Martinson Perinatal HIV Research Unit.
RATIONALE FOR INVOLVING MEN IN FAMILY PLANNING Irina Savelieva, MD, PhD Research Centre of Obstetrics, Gynecology and Perinatology, Russian Society of.
Microbicides: Who, what, where, when and how Rebekah Webb Global Campaign for Microbicides © Salam Dahbor,
Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.
The special challenges of HIV prevention trials EATG Meeting Brussels, Belgium Lori Heise Global Campaign for Microbicides.
What Makes a Successful Trial? MorenikeUkpong Nigeria HIV Vaccine and Microbicide Advocacy Group.
HIV/AIDS BI-ANNUAL REVIEW 2008 Prevention -Goal, Indicators and Targets TACAIDS.
Microbicides: Science, research, and overview of the field Dr Kamini Walia, Indian Council of Medical Research, New Delhi Bindiya Patel, Global Campaign.
HIV/AIDS VACCINE AWARENESS Vaccine 101 Jeremiah Brewer Health and Training Educator African – Americans Reach and Teach Health Ministry.
Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) Session: Voluntary Medical Male Circumcision (VMMC)
National Working Group on Microbicides The Basics of Microbicides Amitrajit Saha PATH January 2007.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
When Will Women Have Choices? Sharon Hillier University of Pittsburgh School and Medicine Microbicide Trials Network IAS, Washington DC, July 26, 2012.
HIV Prevention : Why we need more options for women Wanjiku Kamau Consultant: International AIDS Vaccine Initiative Consultant: International Partnership.
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
Overview of Microbicide Trials Issues and Challenges.
“Standard of Care” The term “Standard of care” refers to the nature of the prevention and/or care that will be provided to participants.
Lori Heise Background and Purpose of Consultation.
Eastern European Alliance for Reproductive Choice REPRODUCTIVE CHOICE FOR HIV- INFECTED WOMEN Prof. POSOKHOVA S.P. UKRAINE УКРАЇНАУКРАЇНА.
Prevention trials pipeline MOSY3. Willard Cates, HIV Prevention Research: The Optimist’s.
How Can Civil Society Measure Value for Money and Prove Its Worth? Amanda Glassman Center for Global Development July 26, 2012.
Thorny Issues in HIV Vaccine Trials Saul Walker Policy Advisor IAVI.
Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,
IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.
AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000 GELS FOR.
PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.
A pill to prevent HIV? For women??
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
HOPE YOU ARE HAVING A GREAT WEEK! What is something new you have learned?
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
New Prevention Technologies Workshop Module 2: NPTs in context
Antiretrovirals for HIV Prevention: Progress and Challenges Kenneth H. Mayer, M.D. Brown/Miriam/Fenway.
ARV-Based Prevention What it means for women Your name here
Factors contributing to diaphragm size change in a Clinical Trial HIV PREVENTION RESEARCH UNIT Govender SM; Mtungwa LN; Manarsingh F; Naidoo VH; Ramjee.
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
Prevention Science Gaps and the HIV/AIDS Pandemic Quarraisha Abdool Karim, PhD Head: CAPRISA Women and AIDS Pogramme Associate Professor in Epidemiology,
PrEP Facts Clinical trials have shown daily oral Tenofovir to effectively prevent HIV acquisition PrEP must only be prescribed for HIV- patients and patients.
Information about HIV Prevention Options
“Its Different Now”: The Changing Landscape of HIV testing
On behalf of The MTN-020/ASPIRE Study Team
HIV and the ART of Prevention
Overview.
PrEP.
A public cervix announcement: CERVICAL BARRIERS in seven minutes
Microbicides: Who, what, where, when and how
Presentation transcript:

new ARV-based prevention tools how the research is happening how we need to be involved Anna Forbes, MSS Consultant, HIV and women’s health HIV Research Catalyst Forum 21 May 2010

differences between treatment trials and prevention trials HIV treatment trials: enroll those who need treatment & may get immediate benefit may help prevent disease progression only benefits those with the disease HIV prevention trials: enrolling healthy people – no immediate benefit to person may help prevent disease transmission benefits society; everyone at risk of HIV

PrEP Clean injecting equipment Cervical barriers: vaginal diaphragms PMTCT Vaccines Voluntary counselling and testing HIV Prevention Microbicides Male and female condoms Male circumcision PEP

what do we need to know? Is the product safe? For whom?  Adolescents? Women – pregnant? breast-feeding?  HIV-negative only? Or HIV-positive also?  Topical products -- vaginal application only? rectal only? Is it effective? For whom?  e.g. circumcision: lowers men’s risk, not women’s Usable with condoms/other barriers?

early-stage concepts preclinical testing human safety trials 3 in large-scale efficacy trials the product pipeline Source: Alliance for Microbicide Development

expected trial results -- effectiveness PrEP Men who have sex with men PrEP Heterosexual men/women PrEP Serodiscordant couples PrEP Injection drug users Treatment Serodiscordant couples PrEP Men who have sex with men PrEP Women First ARV-based Microbicide Women PrEP/Microbicid es Women

what else do we need to know? Does the community see the as ethical?  What roles do they play in set up, implementation, results distribution? Is the test product acceptable?  Do trial participants use it?  Would people use it in real life, after the trial?

going through informed consent Recruitment Participant gets information about the trial in her own language Screening Visit 1: Hears more about trial, gets screened for HIV, STI and pregnancy. Baseline data are collected Screening Visit 2: Gets test results, STI treatment if needed, counselling, info. on trial reinforced Randomization: Participant is assigned by chance to a group Family Planning INFORMED CONSENT to be SCREENED Inform ed conse nt to enrol Condoms + placebo Condoms + experimental gel INFORMED CONSENT to be ENROLLED

who says when research is ethical? Researchers and sponsors Community and advocates Ethics committees Ethical research

the challenge of adherence Prevention technology trials measure both tool + behavior addHow well tool works + How consistently people use it = How well it prevents transmission Effectiveness rate =

educating communities is vital People use a new product when: It is affordable and accessible It works the way they think it will (realistic expectations) Their peers like it and/or use it Its benefit seems worth the effort/cost